GET IN NOW BEFORE THE STOCK GETS DISCOVERED .4 FDA APPROVALS COMING SOON FOLKS.PLEASE DO YOUR OWN RESEARCH TO REALISE THE MEGA POTENTIAL !
4 FDA approvals including a Blockbuster (Monovisc) which alone is worth more than current Market cap .ANIK has been profitable for each of the past seven years.GLTA
2011 Price Target: $30.00+
Anika Therapeutics (ANIK)
Market-Cap: 115 Mil Cash: 26 Mil Price: 8.55
Shares Out: 13.5
UPCOMING MILESTONES :
Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential
Hyaloglide 510(K) expected FDA approval 1Q 2011
Hyalonect 510(K) expected FDA approval 1Q 2011
Hyalofast 510(K) expected FDA approval 1Q 2011
FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:
* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;
* Hyalonect®, a knitted mesh used as a bone graft wrap; and
* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.
We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.
Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.